Obesity and NAFLD. The role of bacteria and microbiota

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 59-71

  Duseja, Ajay ^a   Chawla, Yogesh Kumar ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Endotoxemia; Intestinal permeability; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Probiotics; Small intestinal bacterial overgrowth; Toll like receptors

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; BILE ACID; CHOLINE; CYTOKINE; INSULIN; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; BILE ACID METABOLISM; ENDOTOXEMIA; HOST; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PHOSPHOLIPID METABOLISM; REVIEW; SMALL INTESTINE;

ENDOTOXEMIA; INTESTINAL PERMEABILITY; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; PROBIOTICS; SMALL INTESTINAL BACTERIAL OVERGROWTH; TOLL-LIKE RECEPTORS;

ANIMALS; CYTOKINES; FATTY LIVER; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INSULIN RESISTANCE; INTESTINES; MICROBIOTA; OBESITY; PROBIOTICS; TOLL-LIKE RECEPTORS;

EID: 84888023932     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.002     Document Type: Review

References (64)

1. Neish A.S. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136:65-80.
2. Bäckhed F., Ding H., Wang T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004, 101:15718-15723.
3. Tennyson C.A., Friedman G. Microecology, obesity, and probiotics. Curr Opin Endocrinol Diabetes Obes 2008, 15:422-427.
4. Hugenholtz P., Goebel B.M., Pace N.R. Impact of culture-independent studies on the emerging phylogenetic view of bacterial diversity. JBacteriol 1998, 180:4765-4774.
5. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
6. Nicholson J.K., Holmes E., Wilson I.D. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005, 3:431-438.
7. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
8. Ogden C.L., Carroll M.D., Kit B.K., et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012, 307:483-490.
9. Rychlik J.L., May T. The effect of a methanogen, Methanobrevibacter smithii, on the growth rate, organic acid production, and specific ATP activity of three predominant ruminal cellulolytic bacteria. Curr Microbiol 2000, 40:176-180.
10. Bäckhed F., Manchester J.K., Semenkovich C.F., et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007, 104:979-984.
11. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
12. Ley R.E., Bäckhed F., Turnbaugh P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005, 102:11070-11075.
13. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
14. Kalliomäki M., Collado M.C., Salminen S., et al. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008, 87:534-538.
15. Muccioli G.G., Naslain D., Bäckhed F., et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010, 6:392.
16. Duseja A., Das A., Das R., et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2007, 52:2368-2374.
17. Duseja A., Sharma B., Kumar A., et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology 2010, 52:2248-2249.
18. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
19. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. JHepatol 2006, 45:600-606.
20. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
21. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010, 103:71-83.
22. Duseja A., Das R., Nanda M., et al. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005, 11:393-395.
23. Duseja A., Aggarwal R. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. JGastroenterol Hepatol 2012, 27:848-851.
24. Gäbele E., Dostert K., Hofmann C., et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. JHepatol 2011, 55:1391-1399.
25. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
26. Shanab A.A., Scully P., Crosbie O., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011, 56:1524-1534.
27. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
28. Amar J., Chabo C., Waget A., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011, 3:559-572.
29. Burcelin R., Garidou L., Pomié C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin Immunol 2012, 24:67-74.
30. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
31. Rana D., Duseja A., Dhiman R.K., et al. Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin. Hepatol Int 2013, 7:562-569.
32. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
33. Ruiz A.G., Casafont F., Crespo J., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007, 17:1374-1380.
34. Thuy S., Ladurner R., Volynets V., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. JNutr 2008, 138:1452-1455.
35. Miura K., Seki E., Ohnishi H., et al. Role of Toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract 2010, 2010:362847.
36. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
37. Vijay-Kumar M., Aitken J.D., Carvalho F.A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
38. Szabo G., Velayudham A., Romics L., et al. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of Toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005, 29(Suppl 11):140S-145S.
39. Rivera C.A., Gaskin L., Allman M., et al. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol 2010, 10:52.
40. Csak T., Velayudham A., Hritz I., et al. Deficiency in myeloid differentiation factor-2 and Toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 2011, 300:G433-G441.
41. Brun P., Castagliuolo I., Floreani A.R., et al. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Gut 2006, 55:1212.
42. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139:323-334.
43. Robertson S.J., Rubino S.J., Geddes K., et al. Examining host-microbial interactions through the lens of NOD: from plants to mammals. Semin Immunol 2012, 24:9-16.
44. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
45. Vance D.E. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol 2008, 19:229-234.
46. Spencer M.D., Hamp T.J., Reid R.W., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140:976-986.
47. Trauner M., Claudel T., Fickert P., et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010, 28:220-224.
48. Dekaney C.M., von Allmen D.C., Garrison A.P., et al. Bacterial-dependent up-regulation of intestinal bile acid binding protein and transport is FXR-mediated following ileo-cecal resection. Surgery 2008, 144:174-181.
49. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
50. Frantz J.C., McCallum R.E. Growth yields and fermentation balance of Bacteroides fragilis cultured in glucose-enriched medium. JBacteriol 1979, 137:1263-1270.
51. Amaretti A., Bernardi T., Tamburini E., et al. Kinetics and metabolism of Bifidobacterium adolescentis MB 239 growing on glucose, galactose, lactose, and galactooligosaccharides. Appl Environ Microbiol 2007, 73:3637-3644.
52. Weimer P.J., Zeikus J.G. Fermentation of cellulose and cellobiose by Clostridium thermocellum in the absence of Methanobacterium thermoautotrophicum. Appl Environ Microbiol 1977, 33:289-297.
53. Nardone G., Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. JClin Gastroenterol 2004, 38:S121-S122.
54. Naito E., Yoshida Y., Makino K., et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. JAppl Microbiol 2011, 110:650-657.
55. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
56. Wagnerberger S., Spruss A., Kanuri G., et al. Lactobaccilus casei Shirota protects from fructose-induced liver steatosis: a mouse model. JNutr Biochem 2013, 24:531-538.
57. Velayudham A., Dolganiuc A., Ellis M., et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009, 49:989-997.
58. Loguercio C., Federico A., Tuccillo C., et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. JClin Gastroenterol 2005, 39:540-543.
59. Lirussi F., Mastropasqua E., Orando S., et al. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, (1). CD005165.
60. Pappo I., Becovier H., Berry E.M., et al. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. JSurg Res 1991, 51:106-112.
61. Drenick E.J., Fisler J., Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82:535-548.
62. Neyrinck A.M., Delzenne N.M. Potential interest of gut microbial changes induced by non-digestible carbohydrates of wheat in the management of obesity and related disorders. Curr Opin Clin Nutr Metab Care 2010, 13:722-728.
63. Abrams S.A., Griffin I.J., Hawthorne K.M., et al. Effect of prebiotic supplementation and calcium intake on body mass index. JPediatr 2007, 151:293-298.
64. Daubioul C.A., Horsmans Y., Lambert P., et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005, 59:723-726.